SINTX Secures $3.2M Advanced Ceramic Component Orders
July 16, 2026
SINTX Technologies, Inc, headquartered in Salt Lake City, Utah, USA, has received purchase orders from multiple contract manufacturing customers with a combined value of more than $3.2 million for the production of advanced ceramic components.
The company manufactures silicon nitride ceramic components for customers across a range of industries requiring materials with demanding mechanical, thermal, and chemical properties. SINTX stated that its expertise in silicon nitride supports both proprietary product development and contract manufacturing.
“We are pleased to see continued momentum in our contract manufacturing business,” stated Eric K Olson, chairman and Chief Executive Officer of SINTX Technologies. “We believe these purchase orders reflect continued customer interest in SINTX’s manufacturing capabilities and our ability to support technically demanding component requirements.”
Olson continued, “While our long-term strategy remains focused on expanding our proprietary silicon nitride biomaterials and medical device platform, our contract manufacturing business provides an important source of revenue growth and operational leverage. We believe these orders highlight the value customers place on our technical expertise, manufacturing quality, and ability to produce complex, high-performance ceramic components.
The purchase orders are from several existing contract manufacturing customers. Subject to customer requirements, manufacturing schedules and commercial terms, SINTX expects production and shipments associated with the orders to begin during the second half of 2026 and continue into 2027.
The company stated that revenue from the orders will be recognised in accordance with US generally accepted accounting principles once the relevant performance obligations have been met. The purchase orders remain subject to customary customer requirements and may be modified, delayed, reduced, or cancelled under the agreed commercial terms.
Recent News
- Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
